Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Systemic AL Amyloidosis — Treatment

First-line Second-line SECOND-LINE Systemic AL amyloidosis biopsy-proven Newly diagnosed Transplant-eligible (low stage) Relapsed / refractory Standard Daratumumab + VCd ANDROMEDA ↗ Consolidate Induction → autologous SCT selected fit patients IF naive Daratumumab-based AL amyloidosis ↗ t(11;14) Venetoclax-based biomarker-directed